Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis, Oncology, and Regenerative Medicine Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for COL1A1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | COL1A1 Recombinant Protein (ECD/Specific Domains) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native post-translation modifications. |
View COL1A1 Products |
| Gene Delivery | COL1A1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression assays. |
View COL1A1 Products |
| Benchmark Ab | Anti-COL1A1 Recombinant Antibody Recombinant positive control for binding and neutralization assays. |
View COL1A1 Products |
| Validator | COL1A1 siRNA Set For specific knockdown verification in primary fibroblasts and disease models. |
View COL1A1 Products |
| Related Target A | TGFB1 (Transforming Growth Factor Beta 1) Primary upstream driver of COL1A1 expression and myofibroblast activation. |
View TGFB1 Products |
| Related Target B | LOXL2 (Lysyl Oxidase Like 2) Catalyzes collagen cross-linking; key target for extracellular matrix stabilization. |
View LOXL2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Distinguishing Type I from other collagen types (Type II, III, V) | Sequence-verified recombinant COL1A1 domains designed to minimize homology overlap. |
| Native post-translational modifications (hydroxylation/glycosylation) | HEK293 mammalian expression host ensures native-like processing compared to prokaryotic systems. |
| Assay reproducibility in fibrotic screening | Batch-to-batch consistency with strict endotoxin control (<1.0 EU/μg) and high purity (>95% by SDS-PAGE). |
| Target validation in complex primary cells | Validated siRNA sets and high-titer lentivirus for robust knockdown/overexpression. |
Live COL1A1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Collagen Type I (encoded by the COL1A1 gene) is experiencing a major renaissance. Historically viewed as a passive structural scaffold, COL1A1 is now recognized as a highly dynamic driver of pathology in organ fibrosis (liver NASH/MASH, pulmonary fibrosis, systemic sclerosis) and the oncology stroma (desmoplastic tumors like pancreatic ductal adenocarcinoma).
The race for COL1A1-associated therapeutics is intensifying, with major players shifting focus from systemic TGF-beta inhibition—which is plagued by cardiotoxicity and dose-limiting side effects—to localized ECM-remodeling agents, integrin inhibitors, and direct COL1A1 genetic knockdown therapies (siRNA/ASO). As first-generation antifibrotics reach clinical maturity, the next wave of R&D is targeting the mechanical signaling feedback loop between the stiffened collagen matrix and disease-promoting cells.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| RNA Therapeutics (siRNA/ASO) | Alnylam, Ionis Pharmaceuticals | Hypertrophic Scars, Keloids, Liver Fibrosis | In vitro knockdown validation (Need sequence-verified COL1A1 siRNA and qPCR validators) |
| Monoclonal Antibodies (mAbs) | Gilead, FibroGen | Idiopathic Pulmonary Fibrosis (IPF), Solid Tumors | Epitope mapping and binding affinity (Need high-purity, native-glycosylated COL1A1 proteins) |
| Small Molecule Inhibitors (LOX/DDR) | Pharmaxis, Boehringer Ingelheim | NASH/MASH, Myelofibrosis | Enzymatic and receptor-binding assays (Need recombinant collagen-binding receptors like DDR1/DDR2) |
| Recombinant Collagen (Aesthetics) | Shiseido, Bloomage Biotech | Anti-aging, Tissue Regeneration | Biocompatibility and cell adhesion assays (Need high-purity, endotoxin-free recombinant human COL1A1) |